IL153882A0 - Valsartan salts - Google Patents

Valsartan salts

Info

Publication number
IL153882A0
IL153882A0 IL15388201A IL15388201A IL153882A0 IL 153882 A0 IL153882 A0 IL 153882A0 IL 15388201 A IL15388201 A IL 15388201A IL 15388201 A IL15388201 A IL 15388201A IL 153882 A0 IL153882 A0 IL 153882A0
Authority
IL
Israel
Prior art keywords
valsartan
salts
valsartan salts
Prior art date
Application number
IL15388201A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153882(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL153882A0 publication Critical patent/IL153882A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL15388201A 2000-07-19 2001-07-17 Valsartan salts IL153882A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115556 2000-07-19
PCT/EP2001/008253 WO2002006253A1 (en) 2000-07-19 2001-07-17 Valsartan salts

Publications (1)

Publication Number Publication Date
IL153882A0 true IL153882A0 (en) 2003-07-31

Family

ID=8169294

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15388201A IL153882A0 (en) 2000-07-19 2001-07-17 Valsartan salts
IL153882A IL153882A (en) 2000-07-19 2003-01-09 Calcium salt of valsartan and a process for its manufacture

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153882A IL153882A (en) 2000-07-19 2003-01-09 Calcium salt of valsartan and a process for its manufacture

Country Status (31)

Country Link
US (5) US20030207930A1 (sk)
EP (1) EP1313714B1 (sk)
JP (1) JP4102664B2 (sk)
KR (1) KR100529658B1 (sk)
CN (2) CN1216873C (sk)
AR (2) AR032758A1 (sk)
AT (1) ATE406355T1 (sk)
AU (2) AU2001289672B2 (sk)
BR (1) BR0112665A (sk)
CA (1) CA2415962C (sk)
CY (1) CY1108559T1 (sk)
CZ (1) CZ303389B6 (sk)
DE (1) DE60135560D1 (sk)
DK (1) DK1313714T3 (sk)
EC (1) ECSP034436A (sk)
ES (1) ES2309090T3 (sk)
HK (1) HK1055963A1 (sk)
HU (1) HU229280B1 (sk)
IL (2) IL153882A0 (sk)
MX (1) MXPA03000525A (sk)
MY (2) MY152846A (sk)
NO (1) NO326504B1 (sk)
NZ (1) NZ523557A (sk)
PE (1) PE20020613A1 (sk)
PL (1) PL205715B1 (sk)
PT (1) PT1313714E (sk)
RU (1) RU2275363C2 (sk)
SI (1) SI1313714T1 (sk)
SK (1) SK287558B6 (sk)
WO (1) WO2002006253A1 (sk)
ZA (1) ZA200300285B (sk)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60135560D1 (de) 2000-07-19 2008-10-09 Novartis Ag Valsartan salze
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
SI1467728T1 (sl) * 2002-01-17 2008-02-29 Novartis Ag Farmacevtski sestavki vkljucujoci valsartan in NEP inhibitorje
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
WO2003089417A1 (en) * 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AU2003240670A1 (en) * 2002-05-17 2003-12-02 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
CA2486557A1 (en) * 2002-06-13 2003-12-24 Novartis Ag Calcium salts of indole derived statins
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
ATE393764T1 (de) 2003-03-17 2008-05-15 Teva Pharma Polymorphe formen von valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US20050165075A1 (en) * 2003-03-31 2005-07-28 Hetero Drugs Limited Novel amorphous form of valsartan
US7378531B2 (en) * 2003-04-21 2008-05-27 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
WO2006066961A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
WO2007017897A2 (en) * 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
FR2886642B1 (fr) * 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
JP2010526126A (ja) * 2007-05-07 2010-07-29 シプラ・リミテッド バルサルタンの製造方法
ES2312162T3 (es) * 2007-06-07 2009-02-16 Inke, S.A. Procedimiento para la obtencion de una sal de valsartan util para la preparacion de valsartan.
RU2681081C2 (ru) * 2007-10-05 2019-03-04 Верастэм, Инк. Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ, и способ лечения пролиферативных заболеваний
HRP20230178T3 (hr) 2007-11-06 2023-03-31 Novartis Ag Farmaceutski pripravci temeljeni na nadgradnjama antagonista/blokatora angiotenzinskog receptora (arb) i inhibitoru neutralne endopeptidaze (nep)
EP2222273A2 (en) 2007-11-12 2010-09-01 Novartis AG Liquid compositions comprising valsartan
JP2013532707A (ja) 2010-08-03 2013-08-19 ノバルティス アーゲー 高結晶性バルサルタン
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
CA2824316C (en) * 2011-01-20 2020-07-07 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
CA2902795C (en) 2013-02-28 2021-06-15 Dermira, Inc. Glycopyrrolate salts
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105541741A (zh) * 2016-01-14 2016-05-04 青岛友诚高新技术有限公司 一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) * 2016-07-29 2016-12-21 陈欣怡 一种缬沙坦的新型固体形式
WO2018040065A1 (zh) * 2016-09-02 2018-03-08 诺瑞特国际药业股份有限公司 缬沙坦二钠盐的晶型
TWI648267B (zh) * 2016-09-02 2019-01-21 諾瑞特國際藥業股份有限公司 纈沙坦二鈉鹽新晶型
AU2017349757A1 (en) 2016-10-28 2019-05-30 Biocon Limited Amorphous trisodium sacubitril valsartan and process for its preparation
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
PL3658122T3 (pl) 2017-07-28 2021-10-18 Synthon B.V. Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
EP4037679A4 (en) * 2019-12-02 2023-11-08 Harman Finochem Limited PROCESS FOR PREPARING HIGHLY PURE VALSARTAN

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499017A (en) * 1983-06-06 1985-02-12 Pfizer Inc. Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
DE19675036I2 (de) * 1990-02-19 2004-10-21 Novartis Ag Acylverbindungen.
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
SK117996A3 (en) 1994-03-17 1997-03-05 Ciba Geigy Ag Pharmaceutical composition for treatment of diabetic nephropathy
CA2214143A1 (en) 1995-04-07 1996-10-10 Marc De Gasparo Combination compositions containing benazepril or benazeprilat and valsartan
DK0853477T3 (da) 1995-10-06 2003-02-10 Novartis Ag AT1-receptor-antagonister til forebyggelse og behandling af postiskæmisk nyresvigt og til beskyttelse af iskæmiske nyrer
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DE60135560D1 (de) 2000-07-19 2008-10-09 Novartis Ag Valsartan salze

Also Published As

Publication number Publication date
ES2309090T3 (es) 2008-12-16
RU2275363C2 (ru) 2006-04-27
CA2415962A1 (en) 2002-01-24
CA2415962C (en) 2010-07-06
WO2002006253A1 (en) 2002-01-24
US20070149587A1 (en) 2007-06-28
US20080293791A1 (en) 2008-11-27
HUP0300731A2 (hu) 2003-09-29
EP1313714B1 (en) 2008-08-27
PL360737A1 (en) 2004-09-20
IL153882A (en) 2009-09-01
AU2001289672B2 (en) 2005-12-08
DE60135560D1 (de) 2008-10-09
CZ2003117A3 (cs) 2003-05-14
ECSP034436A (es) 2003-03-10
US20120329844A1 (en) 2012-12-27
SI1313714T1 (sl) 2009-02-28
AR069374A2 (es) 2010-01-20
US20140073677A1 (en) 2014-03-13
KR20030015888A (ko) 2003-02-25
SK552003A3 (en) 2003-07-01
CZ303389B6 (cs) 2012-08-29
JP2004504307A (ja) 2004-02-12
NO20030232D0 (no) 2003-01-17
US9499499B2 (en) 2016-11-22
AU8967201A (en) 2002-01-30
MY152846A (en) 2014-11-28
CN1680341A (zh) 2005-10-12
PE20020613A1 (es) 2002-08-07
AR032758A1 (es) 2003-11-26
MXPA03000525A (es) 2003-05-14
PT1313714E (pt) 2008-11-03
NO20030232L (no) 2003-01-17
HK1055963A1 (en) 2004-01-30
CN100413852C (zh) 2008-08-27
US8278339B2 (en) 2012-10-02
NZ523557A (en) 2004-12-24
PL205715B1 (pl) 2010-05-31
CN1216873C (zh) 2005-08-31
JP4102664B2 (ja) 2008-06-18
CY1108559T1 (el) 2014-04-09
SK287558B6 (sk) 2011-02-04
US20030207930A1 (en) 2003-11-06
ZA200300285B (en) 2004-03-25
HUP0300731A3 (en) 2006-05-29
BR0112665A (pt) 2003-06-24
CN1443176A (zh) 2003-09-17
MY136446A (en) 2008-10-31
DK1313714T3 (da) 2008-12-15
KR100529658B1 (ko) 2005-11-21
ATE406355T1 (de) 2008-09-15
EP1313714A1 (en) 2003-05-28
NO326504B1 (no) 2008-12-15
HU229280B1 (en) 2013-10-28

Similar Documents

Publication Publication Date Title
HK1055963A1 (en) Valsartan salts
AU7847201A (en) Tetrazole derivatives
AU2405002A (en) Dehalogeno compounds
AU7440101A (en) Novel tetrazole derivatives
GB0005200D0 (en) New salt form
GB0015900D0 (en) New salt form
AU146698S (en) Reel
GB0015902D0 (en) Compounds
GB0015853D0 (en) Compounds
GB0003600D0 (en) Compounds
GB0003608D0 (en) Compounds
GB0003609D0 (en) Compounds
GB0018351D0 (en) Compounds
GB0003631D0 (en) Compounds
GB0003633D0 (en) Compounds
GB0003634D0 (en) Compounds
GB0007653D0 (en) Compounds
GB0003637D0 (en) Compounds
GB0004053D0 (en) Compounds
GB0005370D0 (en) Compounds
GB0005574D0 (en) Compounds
GB0015863D0 (en) Compounds
GB0003599D0 (en) Compounds
GB0005576D0 (en) Compounds
GB0019578D0 (en) Polysulphamated compounds